DUARTE, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, founded in 1979, is a major nonprofit in the Medical Research sector that reported $285.3M in total revenue in fiscal year 2023. Revenue surged 25% from the prior year, signaling strong growth momentum. Expenses of $382.5M exceeded revenue, resulting in a 34% operating deficit.
THE SPECIFIC AND PRIMARY PURPOSE OF BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE IS TO DIRECTLY ENGAGE IN THE ACTIVE CONDUCT OF MEDICAL RESEARCH. PLEASE SEE SCHEDULE O FOR A CONTINUATION OF OUR MISSION.
BIOMEDICAL RESEARCH AND DISEASE INVESTIGATIONS, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. BECKMAN RESEARCH INSTITUTE HAS PIONEERED SCIENTIFIC BREAKTHROUGHS RESULTING IN TREATMENTS THAT HAVE IMPROVED...
BIOMEDICAL RESEARCH AND DISEASE INVESTIGATIONS, INCLUDING DNA SYNTHESIS AND CELL ANALYSIS. BECKMAN RESEARCH INSTITUTE HAS PIONEERED SCIENTIFIC BREAKTHROUGHS RESULTING IN TREATMENTS THAT HAVE IMPROVED THE LIVES OF PATIENTS WORLDWIDE. NUMEROUS LIFE-SAVING DRUGS USE PATENTED TECHNOLOGY DEVELOPED AT BECKMAN RESEARCH INSTITUTE. THESE DRUGS INCLUDE SYNTHETIC HUMAN INSULIN (HUMULIN) FOR DIABETES, THE WIDELY USED CANCER DRUGS HERCEPTIN, RITUXAN AND AVASTIN, AND HUMIRA FOR ARTHRITIS. RESEARCHERS AT BECKMAN RESEARCH INSTITUTE UNDERTAKE FUNDAMENTAL INVESTIGATIONS IN DIABETES PROGRESSION AND TREATMENT, IMMUNOLOGY AND IMAGING, INTERFERING RNAS AND HIV TREATMENT, TOTAL SYNTHESIS OF COMPLEX AND THERAPEUTIC NATURAL PRODUCTS, MECHANISMS OF DRUG ACTION, NEUROGENESIS, STEM CELL THERAPY, DNA REPAIR AND RADIATION, AND THE IMMUNOBIOLOGY OF VIRAL INFECTION. THEY HAVE ACHIEVED MAJOR ADVANCES IN RECOMBINANT DNA TECHNOLOGY, MONOCLONAL ANTIBODIES, GENE THERAPY, EPIGENETICS, SI-RNA TECHNOLOGY AND CANCER IMMUNOTHERAPEUTICS. A DEPARTMENT IN BECKMAN RESEARCH INSTITUTE IS DEDICATED TO UNDERSTANDING AND DEVELOPING TREATMENTS BASED ON CANCER'S INTERACTION WITH THE IMMUNE SYSTEM. OTHER RESEARCH HAS IDENTIFIED PROTEINS THAT MAY PLAY CRITICAL ROLES IN IMMUNE RESPONSE AND MAY LEAD TO NEW TREATMENT STRATEGIES. ANOTHER MAJOR EMPHASIS FOR THE BECKMAN RESEARCH INSTITUTE SCIENTISTS IS PERSONALIZED RESEARCH AND MEDICINE -- ANALYZING A PATIENT'S UNIQUE GENETIC PROFILE TO DEVELOP TAILORED THERAPIES FOR THEIR SPECIFIC DISEASE. ALL OF THIS RESEARCH IS UNIQUELY SUPPORTED BY ONSITE MANUFACTURING FACILITIES THAT CAN TEST AND PRODUCE QUANTITIES OF CELL-BASED, GENE-BASED AND MOLECULAR THERAPIES. THESE FACILITIES FURTHER SERVE AS RESOURCES FOR MEDICAL AND SCIENTIFIC RESEARCH CENTERS NATIONWIDE. BECKMAN RESEARCH INSTITUTE SCIENTISTS SERVE AS FACULTY MEMBERS IN CITY OF HOPE'S IRELL & MANELLA GRADUATE SCHOOL OF BIOLOGICAL SCIENCES. THE GRADUATE SCHOOL'S MISSION IS TO TRAIN STUDENTS TO BE OUTSTANDING RESEARCH SCIENTISTS IN CHEMICAL, MOLECULAR AND CELLULAR BIOLOGY. THE SCHOOL IS ACCREDITED BY THE WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES. GRADUATES OF THE PROGRAM, AWARDED A DOCTORATE OF PHILOSOPHY IN BIOLOGICAL SCIENCES, ARE EQUIPPED TO ADDRESS FUNDAMENTAL QUESTIONS IN LIFE SCIENCES AND BIOMEDICINE FOR CAREERS IN ACADEMIA, INDUSTRY AND GOVERNMENT.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $285,315,317 | $229,086,534 | +0.2% |
| Expenses | $382,452,556 | $353,496,343 | +0.1% |
| Net Income | $-97,137,239 | $-124,409,809 | -0.2% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Steven B Fink | Director & Chair of the Board | 2.0 |
Officer
Director
|
$0 | $0 | $0 |
| Charlotte Hubbert PhD | Director | 2.0 |
Director
|
$0 | $0 | $0 |
| Debbie C Thurmond | Director/Professor | 60.0 |
Director
|
$435,306 | $21,713 | $457,019 |
| Emmet Stephenson | Director | 2.0 |
Director
|
$0 | $0 | $0 |
| Julian Husbands MD | Director | 2.0 |
Director
|
$0 | $0 | $0 |
| Norman Payson MD | Director | 2.0 |
Director
|
$0 | $0 | $0 |
| Saro Armenian DO MPH | Director/Professor | 2.0 |
Director
|
$0 | $0 | $0 |
| Selwyn Isakow | Director | 2.0 |
Director
|
$0 | $0 | $0 |
| Stephanie Okey | Director | 2.0 |
Director
|
$0 | $0 | $0 |
| Todd M Binder | Director | 2.0 |
Director
|
$0 | $0 | $0 |
| Cristin J O'Callahan | General Counsel & Corp Secretary | 10.0 |
Officer
|
$186,671 | $341,125 | $1,472,464 |
| Donald J Matthewson | Assistant Treasurer | 12.0 |
Officer
|
$125,464 | $12,060 | $639,380 |
| Jo Ann Escasa-Haigh | Chief Business Officer | 12.0 |
Officer
|
$365,936 | $150,513 | $1,980,192 |
| Robert W Stone | President & CEO | 4.0 |
Officer
|
$300,338 | $1,667,332 | $6,149,982 |
| Yvette Tremonti | Treasurer/Chief Financial Officer | 10.0 |
Officer
|
$0 | $24,162 | $24,162 |
| Ashley Baker Lee | SVP, Research Operations | 48.0 |
Key Emp
|
$872,074 | $132,846 | $1,222,938 |
| David A Horne | Vice Prvst & Depty Dir BRI & Dn Fac Aff | 60.0 |
Key Emp
|
$914,413 | $104,799 | $1,019,212 |
| David Craig | Dep Dir, Integr Transltnl Sci | 60.0 |
Key Emp
|
$428,774 | $14,702 | $443,476 |
| Debra F Fields | Exec VP & Chief Transformation Ofc | 12.0 |
Key Emp
|
$340,881 | $384,116 | $2,088,520 |
| John D Carpten | Chf Sci Off, BRI Dir, Canc Ctr Dir | 33.0 |
Key Emp
|
$571,428 | $100,957 | $1,139,917 |
| Marcellus R Van Den Brink MD PhD | Pres COH LA & NMC & Chf Phys Exec | 6.0 |
Key Emp
|
$99,787 | $157,403 | $1,155,272 |
| Mark Hulse | Chief Digital Officer | 12.0 |
Key Emp
|
$276,672 | $42,307 | $1,425,667 |
| Steven Terry Rosen MD | EVP, Dir Emeritus Comp Canc Ctr & BRI | 54.0 |
Key Emp
|
$1,562,947 | $305,760 | $2,042,368 |
| Edward S Kim | Director, System Clin Trials | 15.0 |
Highest
|
$396,461 | $136,190 | $1,722,035 |
| Harlan Alcon Levine | Pres, Hlth Innovation & Policy | 11.0 |
Highest
|
$364,681 | $403,546 | $2,392,717 |
| Kristin Bertell | Chief Philanthropy Officer | 2.0 |
Highest
|
$41,469 | $314,901 | $1,558,973 |
| Larry Kwak | Deputy Dir, Comp Cancer Ctr | 60.0 |
Highest
|
$1,040,975 | $51,025 | $1,092,000 |
| Vijay Trisal MD | System Chief Clinical Officer | 2.0 |
Highest
|
$37,057 | $148,148 | $1,259,854 |
| Jennifer Parkhurst | Former Officer | 12.0 |
|
$312,857 | $64,845 | $1,629,131 |
| Philip Okala | FORMER OFFICER | 12.0 |
|
$175,540 | $14,345 | $892,045 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $285,315,317 | $382,452,556 | $2,184,814,083 | $-97,137,239 |
| 2023 | $229,086,534 | $353,496,343 | $1,946,470,774 | $-124,409,809 |
| 2022 | $288,276,013 | $367,599,613 | $1,755,270,549 | $-79,323,600 |
| 2021 | $339,177,936 | $341,846,245 | $1,995,828,082 | $-2,668,309 |
| 2020 | $266,229,786 | $368,392,601 | $1,692,642,628 | $-102,162,815 |
| 2019 | $568,398,026 | $426,095,842 | $1,556,201,710 | $142,302,184 |
| 2018 | $585,400,050 | $433,936,266 | $1,472,757,241 | $151,463,784 |
Compare BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE with other nonprofits in California and across the country.